PD‐L2 Expression in Breast Cancer Promotes Tumor Development and Progression
Journal of Immunology Research · 2024
DOI: 10.1155/2024/3145695 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunology Research, 2024. Verfasst von Yuling Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology Suzhou Vocational Health College, Suzh…. Hauptthemen laut MEDLINE: Breast Neoplasms, Disease Progression, Programmed Cell Death 1 Ligand 2 Protein, Cell Movement. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Program of Suzhou, Qinglan Project of Jiangsu Province of China, Jiangsu Provincial Medical Youth Talent.
Abstract (Originalsprache)
Background
This work focused on investigating the role of programmed death ligand 2 (PD‐L2) in the progression of breast cancer by utilizing breast cancer specimens and cells. Materials and Methods . The serum levels of soluble PD‐L2 (sPD‐L2) in breast cancer patients and healthy individuals were analyzed by means of the enzyme‐linked immunosorbent assay, and the PD‐L2 levels within 416 resected breast cancer specimens were assessed through immunohistochemistry. Concurrently, in vitro cell experiments and in vivo animal experiments were carried out to analyze the relationship between PD‐L2 and the invasion and migration of breast cancer.
Results
The concentration of sPD‐L2 in breast cancer patients significantly increased compared to that in the control groups. Additionally, breast cancer patients with high concentrations of sPD‐L2 had higher Ki67 values (≥30%) and tumor grades. PD‐L2 was expressed in 79.09% of the cancer samples, which exhibited a positive correlation with the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). Furthermore, we discovered that knockdown of PD‐L2 inhibited the migratory and invasive abilities of both MCF‐7 and MDA‐MB231 cells.
Conclusion
Our findings demonstrated that knockdown of PD‐L2 suppressed tumor growth, providing novel insights into important biological functions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology Suzhou Vocational Health College, Suzhou 215009, China.
- Center for Drug Metabolism and Pharmacokinetics College of Pharmaceutical Sciences Soochow University, Suzhou 215123, China.
ORCID-Profile: Yuling Sun, Weipeng Wang, Jing Sun
Förderung
- Science and Technology Program of Suzhou
- Qinglan Project of Jiangsu Province of China
- Jiangsu Provincial Medical Youth Talent
- Project 333 of Jiangsu Province
Zitieren
APA
Sun, Y., Yang, J., Chen, Y., Guo, Y., Xiong, J., Guo, X., Zhang, Y., Gu, L., Tong, M., Wang, W., & Sun, J. (2024). PD‐L2 Expression in Breast Cancer Promotes Tumor Development and Progression. Journal of Immunology Research. https://doi.org/10.1155/2024/3145695
Vancouver
Sun Y, Yang J, Chen Y, Guo Y, Xiong J, Guo X, et al. PD‐L2 Expression in Breast Cancer Promotes Tumor Development and Progression. Journal of Immunology Research. 2024. doi:10.1155/2024/3145695
BibTeX
@article{Sun2024,
author = {Sun, Yuling and Yang, Jie and Chen, Yachun and Guo, Yundi and Xiong, Jian and Guo, Xuqin and Zhang, Yawen and Gu, Li and Tong, Min and Wang, Weipeng and Sun, Jing},
title = {PD‐L2 Expression in Breast Cancer Promotes Tumor Development and Progression},
journal = {Journal of Immunology Research},
year = {2024},
doi = {10.1155/2024/3145695}
}
EUVIMED